BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that Dr. Michael Bristow, President and Chief Executive Officer, will be a featured panelist at the New Paradigms to Fund & Move Drug Development, January 11-12, 2012 in San Francisco. Dr. Bristow will be a panelist on the session “Plasma and Imaging Biomarkers that Drive Value and Improve Success Rates,” Thursday, January 12, 2012 at 11:15 a.m. Pacific.
